Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an ...

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) published two positive announcements yesterday. The first concerns ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

A federal judge denied Teva's bid to delay the first Paragard bellwether trial, keeping a January start date for claims tied ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up ...

Teva and Royalty Pharma have signed a deal worth up to $500 million to advance TEV-408, a drug being tested for vitiligo and ...

Royalty Pharma and the US affiliate of Israel’s Teva Pharmaceutical Industries have announced a funding agreement of up to ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best performing pharma stocks in 2025. Truist lifted the ...

Pivot to Growth Strategy Progress : Teva is accelerating its Pivot to Growth strategy, focusing on transforming into a leading innovative biopharmaceutical company through late-stage innovative ...

Six months on, Teva’s new “pivot to growth” strategy appears to be paying off. In 2023’s third quarter, the Israeli-American generics giant reported global sales of $3.9 billion, up 7% from the same ...

Teva Pharmaceuticals can’t delay the first trial in thousands of lawsuits over claims its Paragard intrauterine contraceptive ...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 ...